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Background: Smoking is thought to produce an appetite-suppressing effect by many smokers. Thus, the fear of body weight gain often
outweighs the perception of health benefits associated with smoking cessation, particularly in adolescents. We examined whether the
tobacco industry played a role in appetite and body weight control related to smoking and smoking cessation. Methods: We performed
a systematic search within the archives of six major US and UK tobacco companies (American Tobacco, Philip Morris, RJ Reynolds, Lorillard,
Brown & Williamson and British American Tobacco) that were Defendants in tobacco litigation settled in 1998. Findings are dated from 1949
to 1999. Results: The documents revealed the strategies planned and used by the industry to enhance effects of smoking on weight and
appetite, mostly by chemical modifications of cigarettes contents. Appetite-suppressant molecules, such as tartaric acid and 2-acetylpyridine
were added to some cigarettes. Conclusion: These tobacco companies played an active and not disclaimed role in the anti-appetite effects of
smoking, at least in the past, by adding appetite-suppressant molecules into their cigarettes.
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Introduction
Tobacco is a major cause of death in developed countries.
1,2 Smoking is
thought to produce an appetite-suppressing effect by many smokers,
particularly in adolescents.3 Most smokers want to stop smoking, but the
fear of body weight gain might outweigh the perception of potential
health benefits associated with smoking cessation, particularly in
women.4–7 For instance, female students concerned about their weight
are at an increased risk of initiating smoking.8 In general, smokers have a
lower body mass index (BMI) than non-smokers.9 Six months after
smoking cessation, the mean body weight gain is estimated 3.5 kg.10
Among sedentary smokers, weight gain might even be higher.11,12
Smoking and weight share a complex relationship.13 On one hand, on
average, smokers have a lower BMI than non-smokers and sustained
quitters have the same BMI than never smokers. On the other hand,
heavier smokers defined as either nicotine-dependent smokers or
smokers of more than a pack a day, have a higher BMI than lighter
smokers.14–17 In longitudinal studies, smoking cessation is associated
with weight gain.18,19 Hypotheses about the cause of post-cessation
weight gain involve increased energy intake by alteration of food prefer-
ences, food intake as a substitute for cigarette, as well as decreased energy
expenditure by suppression of the stimulating effect of nicotine on
metabolic rate.19
Following the 1998 ‘Master Settlement Agreement’ between US
tobacco industry and 46 States, US tobacco companies made their
internal documents available on the Internet.20 Previous research into
the archives of tobacco companies have helped the health-care
community to understand the industry’s strategies.21 To our
knowledge, no study has explored the industry’s knowledge of the link
between smoking and appetite or body weight and how such a link was
used to promote tobacco products.
The objective of our study was to answer the following questions:
did the tobacco industry try to take advantage of the relationships
between body weight, appetite, smoking and smoking cessation?
Did it go as far as modifying its products to obtain such
advantages?
Methods
We conducted a systematic search within the archives of six major
tobacco companies (American Tobacco, Philip Morris, RJ Reynolds,
Lorillard, Brown & Williamson and British American Tobacco) that
were defendants in tobacco litigation settled in 1998.20,22 We retrieved
the documents online from the Legacy Tobacco Document Library.23 The
search identified documents by means of a search using keywords such as
‘Body weight gain’, ‘Appetite’, ‘Weight control’, ‘Relapse’, etc. Then,
using a ‘snowball sampling method’,22 other documents were found.
Our results are presented and grouped by theme; they do not follow a
strict chronological order. Documents presented in this article are dated
from 1949 to 1999.
Results
Industry’s projects to add substances to cigarettes with
effects on body weight and appetite
Since the 1960s, tobacco companies intended adding appetite suppressant
in cigarettes to attract new smokers concerned about their body weight.
PM stated in a 1965 internal memorandum: ‘If we were able to develop
cigarettes which are much ‘‘safer’’ than the existing ones [. . .] and which
also act as appetite depressants, then we may uncover a new market of
smokers. The potential smokers would be the non-smokers who are more
concerned with losing weight than with contracting respiratory or blood
circulatory illnesses. [. . .] To develop new smoking products which will
be low in tobacco tar, low in tobacco gas and rich in appetite-depressing
factors’ (Bates no. 2056159412). In a 1971 internal memorandum about
‘New Product Ideas’, PM discussed the possibility of creating a cigarette
that controlled appetite, either by stimulating or reducing it. Under
‘Specific Appetite Inducers’ they contemplated the following course of
action: ‘Incorporate special herbs or medications in a cigarette form as
appetite stimulants or possibly for tension release. Especially for people
who live alone (elderly) or business men to stimulate appetite’. PM also
considered an ‘Alternate product’ containing an ‘appetite suppressant
ingredient’ (Bates no. 1000300217/0220). One year later, this company
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envisaged the creation of ‘cigarette products which are marketed as
appetite reducers (sweet tasting) or thirst-inducing companion for beer
or other beverages (salty). The former relies its efficacy on the empirical
evidence that conventional cigarets [sic] depress appetite; the sweet taste
is not intended to change blood sugar levels, but merely to provide a
sensory confirmation that appetite is being reduced’ (Bates
no.1000110930/0933). In 1988, PM investigated the possibility of
creating ‘a slimmer Marlboro’, an ‘updated Marlboro that’s more
attractive to female’, in which it would ‘make it an appetite depressant’
(Bates no.506656719–506656749).
The PM documents contained also some drawings—seemingly
resulting of a brainstorming—showing how addition of ‘appetstat [sic]
grains’ could be put inside the cigarette filter: the ‘sweet’ ones depress
appetite, and the ‘salt’ ones stimulate thirst and appetite (Bates no.
1000110840/0922). In 1981, PM stated in an internal report: ‘It was
noted that one beneficial attribute ascribed to smoking is appetite
suppressance [sic]. A thorough study of this effect and publication of
the results may have a beneficial impact on the image of smoking. If
particular compounds responsible of this effect could be found, it
might be possible to enhance the effect in a cigarette aimed at people
desiring help with weight control. Care must be taken not to make
specific claims or to invoke a ‘‘drug additive’’ image. This is simply a
natural effect of the product and/or its use’ (Bates no.1003395096/5101).
The company was aware that advertising the appetite suppression
characteristic of cigarettes as a benefit would entail the risk of potential
Food and Drug Administration (FDA) interference (Bates no. 01587028/
7036; Bates no. 500417387; Bates no. 1003395088/5092; Bates no.
621007557).
During the 1970s, Lorillard also explored the ‘technical feasibility of [. . .]
use of active agents beyond nicotine which might provide an additional
dimension of physiological effect—facilitate/depress sleepiness, enhance/
reduce appetite feeling [. . .]’ (Bates no. 81564000/4004). In 1976, its
scientists suggested a new brand that would ‘give smokers an additional
benefit that is different, but compatible with traditional cigarette benefits.
(An example here might be the addition of an appetite depressant to the
cigarette to help dieting)’ (Bates no. 80635192/5195). Lorillard scientists
raised the following questions: ‘How to enhance whatever effect elements
like nicotine already has for benefits like weight control’, ‘How to help
with weight control’, ‘How to address weight control without adding
pharmacological agency’ and ‘How to convince consumer[s] [a]
cigarette is [a] weight control agent’ (Bates no. 83910635/0661). They
concluded in 1979 that: ‘Revolutionary Next Era possibilities suggested
by our Agencies [included]: [. . .] Use of the cigarette to deliver another
benefit like an appetite depressant’ (Bates no. 03547249/7251; Bates no.
01399043/9049). This company thought of turning the prospective
appetite-reducing cigarette into a marketing advantage. Already, in
1974, Lorillard devised the following slogan regarding the Trims
cigarettes: ‘This new longer length cigarette actually contains an
appetite depressant to keep you looking and feeling as slim and trim as
your cigarette’ (Bates no. 01587028/7036). Tartaric acid was added to its
Trims cigarettes for its appetite-suppressant effect. However, this tobacco
product was no longer considered only as a cigarette but as a drug by the
FDA that won a case against the Lorillard Company in 1977. The de-
scription of the judgement was the following: ‘the product is intended to
affect for the ingestion of food and thereby achieving a reduction in the
body’s weight’, and ‘based solely upon that claim held that it was a drug’
(Bates no. 1003045052/5092).
The RJR Company also launched the development of a weight control
cigarette product. In 1982, they searched ideas about ‘a cigarette concept
that turns build-up into an appetite suppressant’ (Bates no. 502788460–
502788508). In 1988, they devised new cigarettes, which suppressed
appetite: ‘For diets as well as for when you are hungry but it’s not time
[to] break for lunch yet’ (Bates no. 521386038/6045). A RJR scientist, in a
memorandum about ‘Project FD’ [Future Dimensions], reported ‘the
psychological and physiological state of human[s] can be strongly
influenced by both aromatic and odourless compounds. Herein lies a
fascinating new business/product opportunity for both the tobacco and
food operation[s] of RJR Nabisco’. The author explained one of the
concepts of Project FD: ‘Hunger control—food aromas with ‘‘mouth
fullness’’ stimulation’ (Bates no. 521386038/6045).
Specific industry’s projects to add substances with an
effect on appetite
Our research identified several substances with an effect on appetite, used,
or intended to be used, by the industry (table 1).
As mentioned above, ‘tartaric acid’ has been the anti-appetite molecule
added to the Lorillard Trims cigarettes (Bates no. 1003045052/5092).
Before that case, in 1961, a PM document entitled ‘Additives to
smoking tobacco’ listed numerous patents of substances that were
added to cigarettes, and gave the reasons for their use. The patent
‘Ferguson 2 773 785’ was then used as ‘an appetite reducer which dries
and puckers the mouth, etc. comprising additive of tartaric acid’ (Bates
no. 2028665546/5552). The patent description of this additive found in
the PM archives explained in details the putative mechanism of action
of this ‘new and improved therapeutic appetite satient composition
designed to curb the appetite without supplying calories to the body and
particularly to a therapeutic appetite satient composition in combustible
from which can be smoked and upon smoking causes loss of appetite’
(Bates no. 2026479779–780). We did not find any other arguments
suggesting a link between Edgar A. Ferguson and the tobacco industry.
Tartaric acid has also been claimed as an ingredient on the ‘UK
Tobacco Additives’ list (of unknown date) held in BAT documents
(Bates no. 321973087–321973167).
2-Acetylpyridine is a molecule patented for its appetite-suppressant
effect.24 It has been used as a cigarette ingredient, as by PM, B&W,
BAT and RJR (its chemical codename is 1122-62-9) (Bates: 605006573;
Bates no. 2078541185; Bates no. 508403623; Bates no. 508403623/3699;
Bates no. 2078541185/1198; Bates no. 321973087–321973167). In a con-
fidential 1995 memorandum, PM researchers expressed their interest in
the appetite-suppressant effect of 2-acetylpyridine and reported some
independent scientific research about its effect. This molecule ‘smells
like corn chips’, and might have anti-smoking properties25 (Bates no.
2075008887/8888).
Tobacco industry investigated additional substances for their anti-
appetite effects, but they were not found in cigarette ingredients
lists: ‘Ephedrine and amphetamine’, two well-known sympathico-
mimetic appetite suppressants, were considered as cigarette ingredients
in the 1960s. In 1968, a RJR scientist wrote: ‘SM67A, an ephedrine
congener, was tested for anorexic activity in rats. In comparison with
standard anorexics, SM67A was found to have some anorexic activity’
(Bates no. 502799201). In 1972, RJR sent a list of ingredients containing
SM67A to a company called Uniroyal Chemical for chemical analysis
(Bates no. 508370235/0237). In 1969, American Tobacco was also
interested in ephedrine through ‘Project PAC-S-P-69’, where PALL
MALL cigarettes were evaluated with the following additives: ‘caffeine
10%, theophylline 10%, theobromine 10% and ephedrine 5%’ (Bates:
950077074). A PM scientist, reporting on his participation at the Tenth
Annual Meeting of the Society of Toxicology, made the following recom-
mendations: ‘As a result of the meeting I would suggest the following
studies: (i) the combined effects of nicotine and ethanol on metabolism of
each one; (ii) the combined effects of nicotine and barbiturates; (c) the
combined effects of nicotine and caffeine; (d) the combined effects of
nicotine and amphetamines’ (Bates no. 1003702971/2974). In 1967, RJR
performed the synthesis of molecules where the phenyl group of drugs
such as amphetamine was replaced by a pyridyl group. This new
compound was thought to ‘conceivably lead to an appetite depressant
(anorexient) without undesirable nervous stimulation’ (Bates no.
500613441). Nevertheless, the potential increase in the risk of cardiac
arrhythmias when combining caffeine, ephedrine, etc, with nicotine was
known by the industry. For example, this medical information about
nicotine and heart disease toxicity that mentions the role of ephedrine
(Bates no. 517585341/5810) was held by RJR.
‘‘N2O (‘laughing gas’)’’ was investigated by Lorillard, as an appetite
suppressant (Bates no. 80635192/5195). In April 1976, during a
discussion on new brand possibilities, Lorillard researchers mentioned:
‘Additional positive benefits—1. A cigarette that helps weight reduction
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by increasing some component already in the smoke, e.g. NO2 [sic]. This
cigarette either depresses appetite or makes all foods taste flat; acting as an
anti-MSG [monosodium-glutamate]. This cigarette is endorsed by weight
watchers’ (Bates no. 80635192/5195). In June of the same year, during the
‘Lorillard Problem Laboratory’, ‘ideas’ were discussed, notably the ‘use of
laughing gas (already in tobacco) as appetite depressant’ (Bates no.
01345589/5596).
‘Menthol’ was mentioned in a 1952 letter from B&W to an expert,
entitled ‘Effect of mentholated cigarettes on appetite’, asking whether
the menthol added to mentholated cigarettes could ‘take the edge off
the smoker’s appetite any more than a similar cigarette without
menthol’. The expert answered that menthol had an inconclusive effect
on smoker’s appetite (Bates: 650203535). In 1971, Liggett & Myers,
looking at ‘New Opportunities in the Menthol Cigarette Market’,
observed: ‘weight control’ has substantial appeal [. . .]. Filters-with-and-
without menthol are credited with suppressing appetite. Salem, as the
cross-over ‘‘bridge’’ between filters-and-menthols, in combination with
Salem’s feminity, fulfils weight control expectations’ (Bates no.
LG0110469–LG0110548).
‘Mariolide’ was studied by the tobacco industry and described as a
‘brain stimulant compound’ (Bates no. 504175618/5619). In 1966, RJR
scientists investigated mariolide as an appetite suppressant: ‘An
experiment was conducted to determine whether mariolide has any
appetite-suppressing properties or not. [. . .] This experiment shows
that the mariolide does have an ability to decrease food intake but that
it occurs at very high doses. The mariolide would not be expected, in the
light of these experiments, to have value as an anorexic agent’ (Bates no.
504724009/4012).
‘Propylene glycol’ was listed in Lorillard’s documents in 1981, and one
of its major pharmacological effects was ‘appetite depressant’ (Bates no.
88698405/8407).
‘Reserpine’, an anti-hypertensive and a tranquilizer, was mentioned in
the famous ‘Project HIPPO II’ conducted by the Battelle Institute in
Geneva for BAT—which investigated the addictive role of nicotine for
the first time—as having some effects on appetite. It was observed that
reserpine ‘decreased very slightly the appetite in our ‘‘appetite test’’ on
rats [. . .]’ (Bates no. 680143705/3741).
Discussion
Our search inside the tobacco documents uncovers the tobacco industry’s
attitude towards weight control related to smoking. The industry made
plans and strategies on how to enhance the effects of smoking on appetite
and body weight through adding substances acting as anti-appetite
agents. Additionally, we found that the industry has added some
substances acting as appetite suppressants into cigarettes.
PM put during the 1960s a substance containing tartaric acid into its
cigarette in order to reduce smokers’ appetite. Tartaric acid was
considered as an appetite suppressant and removed from the market in
1977 by a decision of a US court. This substance was also added to BAT
cigarettes, although we did not find at which date, and if it is still the case.
The Ferguson’s patent description was the only information we can find
on the anti-appetite putative role of tartaric acid in the medical and
chemical literature. The substance 2-acetylpyridine is also claimed as an
appetite-reducing molecule and is one of the tobacco additives, disclosed
on many past lists of cigarette ingredients. No independent studies about
the role on appetite of other substances mentioned in our study were
found in Medline or Cheminfo databases.
Our findings must help smokers and the health-care community to
understand at least partially why cigarette smoking is producing the effect
of reducing appetite, and could explain in part why smokers weigh in
general less than non-smokers. Although little is known in the medical
literature about the anti-appetite effect of the above cited substances, we
can make the hypothesis that the weight gain following smoking cessation
could be a ‘rebound effect’ of discontinuation of the daily consumption
of an anti-appetite substance through cigarette smoking, as it is known
for the use of other anti-appetite substances.26
The tobacco industry, as we saw it with the Lorillard Trims cigarettes
case, has had no advantage to claim the use of their anti-appetite additive.
In a PM memorandum dated from 1969, M. H. Wakeham, a scientific
director, simply explained why they did not need to declare which
additives are put into cigarettes: ‘In the response to Roger’s [Fagan]
question concerning FDA requirements on the introduction of a
substance into cigarettes, I told him that the FDA had no requirements
until a health claim is made. Then there must be studies on safety,
efficacy, mechanism of action, metabolism, etc. If a substance is simply
added to a product and no claims are made there is no need for FDA
approval’ (Bates no. 1001880474).
The major limitation of our study is the scattered nature and relatively
small volume of tobacco industry documents related to our topic. Clearly,
the restrictions inherent to the filing and indexing system of the
industry’s archives are problematic when conducting a systematic
review of documents; the indexing system of archives is not always
consistent and full-text research tools might not recognize words due
to the poor quality of scanned documents. However, this alone is not
sufficient to explain the relative scarcity of the documents we retrieved. It
can be hypothesized that large amounts of material have disappeared,
either by exclusion from the database or destruction by the industry.
Indeed, some documents that we retrieved can only be understood in
the context of activities or projects, which must have generated further
documents of which no trace was found, in spite of our varied attempts.
Another shortcoming is the lack of current documents, the most recent
document on which our work is based dates back to the late 1990s—this
is a general problem that affects all research topics: since it knows its
internal documents may turn up publicly (i.e. since 1998), the industry
can be expected to be much more wary about leaving a written trace of
activities that may be compromising. In spite of these shortcomings, we are
confident that we used the research method recognized by the scientific
community as the most suitable for obtaining a good understanding of the
general attitudes, knowledge and activities of the tobacco industry
regarding the issue of weight control.22,27–29
Table 1 Substances investigated and/or added for body weight control by tobacco industry and their putative mechanism(s) of action
Substances Putative mechanism(s) of action
Tartaric acid Appetite-suppressant effect via drying of the mouth: tartaric acid volatilizes and is reformed in the
mouth. Tartaric acid acts on the membranes in the mouth and produces a dryness that has an
appetite-reducing effect.
2-Acetylpyridine Appetite-suppressant effect via neutralization of the olfactory stimulus.
Catecholamine: ephedrine, amphetamine Appetite-suppressant effect via dopaminergic stimulation.
Laughing gas Appetite-suppressant effect via modifications of the taste of food.
Menthol Appetite modifications via diminution of upper airways irritation.
Mariolide Anorectic effect not eventually described.
Propylene glycol Potential appetite-suppressant effect not eventually described.
Reserpine Decrease of brain activity resulting in a decrease in salty food intake in rats.
236 European Journal of Public Health
In conclusion, we found clear evidence that every one of the six US and
UK tobacco companies elaborated the idea to put appetite depressants
molecule inside cigarettes to enhance this effect. They all investigated
various substances for such a use. At least two of them, PM and BAT
has actually modified its products to affect appetite and body weight. We
already knew the industry modified its products to enhance addiction and
dependence.30 In addition, specific analyses of cigarette contents could be
performed, looking especially for substances that could modify food intake
or body weight, such as ephedrine. Research into the tobacco industries’
archives should be pursued to improve understanding of companies’
strategies, although we should take into account that it is highly possible
that the past and present more sensitive documents are being removed
from these databases by the industry.31,32 The scientific community is most
probably powerless towards this issue. As recommended by the World
Health Organization’s Framework Convention on Tobacco Control,
strict regulation of cigarette and tobacco additives is needed as part of
the fight against tobacco dependence and smoking induced diseases.33
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Key points
 The tobacco industry has added into cigarettes some appetite
suppressants substances, e.g. tartaric acid.
 The tobacco industry made strategies on how to enhance the
effects of smoking on appetite and body weight through adding
substances acting as anti-appetite agents.
 These findings are new arguments to implement a strict
regulation of cigarette and tobacco additives.
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